Alivus Life Sciences to invest more in research in its new avatar.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences, is planning to ramp up its research and development investments as it transitions to its new corporate identity. The company's leadership, including Managing Director and Chief Executive Yasir Rawjee, outlined growth strategies focused on high-value opportunities, geographic expansion, and enhanced operational efficiency.

“We will continue to focus on high-value opportunities and diversifying geographically. As we invest more into the business, we aim to build new levers to drive future growth,” Rawjee said. He also confirmed that Alivus is set to open its own research and development facility within the next 18 months.

When asked about any changes in strategy with the company’s rebranding, Rawjee explained that past investments were mainly directed toward increasing capacities to support business growth, with a key exception being the oncology platform introduced two and a half years ago. He added that the company is now focusing on developing new platforms to fuel growth, some of which are already prepared for implementation, though he withheld specific details for competitive reasons.

In September 2023, Glenmark Pharmaceuticals sold a 75% stake in Glenmark Life Sciences to Nirma Ltd for ₹5,651 crore, marking a pivotal moment in the company’s restructuring.

For the third quarter of FY25 (Q3), Alivus reported a revenue of ₹641 crore, reflecting a 12% year-on-year growth. Its Profit After Tax (PAT) for the quarter stood at ₹137 crore, up from ₹119 crore in the same period last year. The company’s growth was attributed to performance in both the GPL (former parent Glenmark Pharmaceuticals Ltd) and non-GPL segments, with strong contributions from markets like India, Europe, the rest of the world, and Japan.

Alivus Chief Financial Officer Tushar Mistry highlighted the company’s record quarterly revenue, noting steady gross margins of 56%. "Our EBITDA grew by 15.2% year-on-year, showcasing our ability to diversify our product range while maintaining strict cost efficiency," Mistry said.

HBL